Alnylam Pharmaceuticals (ALNY) Cash & Equivalents (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Cash & Equivalents for 18 consecutive years, with $1.7 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents rose 53.39% year-over-year to $1.7 billion; the trailing twelve-month figure through Jun 2026 stood at $1.7 billion (up 53.39% YoY), and the FY2025 full-year result was $1.7 billion, up 71.09% from the prior year.
• Cash & Equivalents steadied at $1.7 billion in Q2 2026 per ALNY's latest filing, from $1.7 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $1.7 billion in Q1 2026 and bottomed at $534.1 million in Q1 2022.
• Historically, Cash & Equivalents has averaged $1.0 billion across 5 years, with a median of $994.2 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents declined 22.82% in 2022, then surged 71.09% in 2025.
• Over 5 years, Cash & Equivalents stood at $868.6 million in 2022, then slipped by 6.43% to $812.7 million in 2023, then increased by 19.19% to $968.7 million in 2024, then soared by 71.09% to $1.7 billion in 2025, then rose by 3.08% to $1.7 billion in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $1.7 billion, $1.7 billion, and $1.7 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.